Konstas, Anastasios-Georgios
Boboridis, Konstadinos G. http://orcid.org/0000-0002-0471-0371
Athanasopoulos, Georgios P.
Haidich, Anna-Bettina
Voudouragkaki, Irini C.
Pagkalidou, Eirini
Katsanos, Andreas http://orcid.org/0000-0001-6623-8503
Katz, L. Jay
Funding for this research was provided by:
This research was funded in part by Santen.
Article History
Received: 26 October 2022
Revised: 9 April 2023
Accepted: 11 May 2023
First Online: 23 May 2023
Competing interests
: AGK: Research funding from Allergan, Bayer, Omni Vision, Pharmaten and Santen; travel support and congress expenses from Vianex and Zwitter; honoraria from Allergan, Esteve Pharmaceuticals, Santen and Vianex. KGB: Honoraria from Laboratoires Théa, Bausch & Lomb, Santen and Novartis. GPA, ABH, ICV and EP: No conflicts of interest. AK: Honoraria and congress expenses from Cooper SA, Santen, Vianex, Zwitter; research funding from Laboratoires Théa. LJK: Grants and research support from Allergan, Diopsys, Heidelberg Engineering, Alcon, Zeiss, Olleyes; consultant/advisory board: Olleyes (stock options); honoraria from Allergan, Glaukos, Bausch & Lomb; Stock shareholder: Glaukos, Mati Therapeutics, Aerie, Olleyes; employment (salary): Glaukos (Chief Medical Officer).
: The research protocol was approved by the Institutional Review Board of the Medical School of Aristotle University and was registered with ClinicalTrials.gov (NCT04673604). The study was conducted in accordance with the tenets of the Declaration of Helsinki.